Viemed Healthcare Inc

VMD remains in a Stage 2 advance with a bullish medium-term bias anchored by a rising 50 and 200 SMA. Short-term price has pulled back into rising EMAs and is oversold, lacking clear acceptance above the 9 and 21 EMA. We recommend stalking for a deeper test of the EMAs or the mid-May swing low support before engaging.

• ↑Q2 revenue $78.1M (+24% YoY) driven by organic growth and Lehan acquisition
• ↑PAP therapy patients +57% YoY; ventilator count at record highs
• ↓Gross margin declined to 57.7% as lower-margin services expand